The following is a summary of “Completed suicide in patients with skin disease: A systematic review and meta-analysis,” ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Hidradenitis Suppurativa (HS) is getting increased attention from dermatologists due to its frequent misdiagnosis and ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 ...

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

RBC Capital notes that Incyte (INCY) has reported much-anticipated phase III top-line data for povorcitinib in hidradenitis suppurativa, ...